Teva Pharmaceutical Industries Ltd. said Monday it will pay $60 million to OncoGenex Pharmaceuticals Inc. under terms of a new global licensing and partnership agreement covering OncoGenex’s potential cancer treatment OGX-011. However, shares of OncoGenex…

Email this Article
Add to del.icio.us
Add to digg
Add to Facebook




Teva Pharmaceutical Industries – Cancer – Business – Biotechnology and Pharmaceuticals – Pharmaceutical

Read more from the original source:
Teva, OncoGenex sign drug development deal